Several EGFR tyrosine kinase inhibitors are recommended by international guidelines as first-line treatment for patients with EGFR mutations. While tissue biopsy samples continue to be the gold standard, it is not feasible in all patients. Join the webinar to hear from Dr. Noemi Reguart and Dr Kuo Chih-Hsi on how liquid biopsy provides a non-invasive option for patients in order for them to access molecular testing….
Cancer Type: Lung
The importance of EGFR CDx testing and recent treatment updates in early stage NSCLC
Several EGFR Tyrosine Kinase Inhibitors are recommended by international guidelines as first-line treatment for patients with EGFR mutations. A robust and approved Companion Diagnostic (CDx) assay is preferred to properly identify eligible patients. Join the webinar to hear from Dr. Noemi Reguart and Dr. Shanop Shuangshot on the importance of EGFR CDx testing; and treatment updates in early-stage EGFR-positive NSCLC….
Lung Cancer Diagnostics Post COVID – a Multidisciplinary View
Various diagnostic tools play indispensable roles in diagnosing, staging, treatment selection & monitoring of lung cancer patients. Join the webinar to hear from pulmonologist Dr James Ho, cardiothoracic surgeon Dr Anand Sachithanandan, and medical oncologist Dr Takayuki Takahama on how diagnostics algorithms (including biomarkers and other testing modalities) influence decisions on targeted therapy selection; and how COVID has impacted management of oncology patients….
Cancer genomic testing | Jennifer’s story
Comprehensive genomic profiling (CGP) is a method of cancer genomic testing used to reveal the unique set of mutations within the cancer’s DNA which determine how the tumour behaves and grows. Here, Jennifer Cole and her oncologist, Dr Jeffrey Rothenstein, discuss how the insights from CGP helped guide Jennifer’s treatment plan and enabled them to find a therapy personalised to her tumour’s unique genomic profile….
NGS and precision oncology in Hong Kong: insights from Dr Lam Tai-Chung
In this article, Dr Lam Tai-Chung shares how his institution has had first-hand experience of landmark cases and outstanding treatment responses from using NGS in seemingly terminal patients. …